ATE333892T1 - Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen - Google Patents
Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelenInfo
- Publication number
- ATE333892T1 ATE333892T1 AT97906433T AT97906433T ATE333892T1 AT E333892 T1 ATE333892 T1 AT E333892T1 AT 97906433 T AT97906433 T AT 97906433T AT 97906433 T AT97906433 T AT 97906433T AT E333892 T1 ATE333892 T1 AT E333892T1
- Authority
- AT
- Austria
- Prior art keywords
- biologically active
- cationic lipid
- receptor ligand
- active molecules
- facilitated administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1136896P | 1996-02-09 | 1996-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE333892T1 true ATE333892T1 (de) | 2006-08-15 |
Family
ID=21750086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97906433T ATE333892T1 (de) | 1996-02-09 | 1997-01-29 | Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen |
Country Status (7)
Country | Link |
---|---|
US (1) | US6077834A (de) |
EP (1) | EP0904100B1 (de) |
JP (1) | JP4512882B2 (de) |
AT (1) | ATE333892T1 (de) |
AU (1) | AU2112697A (de) |
DE (1) | DE69736385T2 (de) |
WO (1) | WO1997028817A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030069173A1 (en) | 1998-03-16 | 2003-04-10 | Life Technologies, Inc. | Peptide-enhanced transfections |
JP4430135B2 (ja) * | 1995-11-30 | 2010-03-10 | バイカル インコーポレイテッド | カチオン脂質複合体 |
US6803360B1 (en) | 1996-12-30 | 2004-10-12 | Georgetown University | Compositions and methods for reducing radiation and drug resistance in cells |
EP0988030A1 (de) * | 1997-06-13 | 2000-03-29 | The Johns Hopkins University | Knobby nanosphären |
US6749863B1 (en) * | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
WO1999025320A1 (en) * | 1997-11-19 | 1999-05-27 | Georgetown University | Targeted liposome gene delivery |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
ATE483816T1 (de) * | 1998-11-19 | 2010-10-15 | Univ Georgetown | Systemisches virus/ligand genabgabemittel und gentherapie |
US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
US9034329B2 (en) | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
ES2366100T3 (es) * | 1999-02-22 | 2011-10-17 | Georgetown University | Inmunoliposomas dirigidos mediante un fragmento de anticuerpo para la administración sistémica de genes. |
US7780882B2 (en) | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
JP2005505231A (ja) * | 2000-11-03 | 2005-02-24 | リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 表面トランスフェクションおよび発現法 |
WO2002076448A1 (en) * | 2001-03-23 | 2002-10-03 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
DK1377320T3 (da) * | 2001-04-04 | 2009-02-09 | Nordic Vaccine Technology As | Polynukleotidbindingskomplekser omfattende steroler og saponiner |
US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US20110135725A1 (en) * | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
MX2008014362A (es) | 2006-05-15 | 2008-11-27 | Univ Georgetown | Preparacion de inmunoliposomas dirigidos a anticuerpos o a fragmentos de anticuerpos para la administracion sistemica de agentes terapeuticos o de diagnostico y usos de los mismos. |
US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
RU2537262C2 (ru) * | 2009-07-08 | 2014-12-27 | Общество С Ограниченной Ответственностью "Фарма Ген" | Молекулярные конъюгаты с поликатионным участком и лигандом для доставки в клетку и ядро клетки днк и рнк |
TWI689314B (zh) | 2010-11-30 | 2020-04-01 | 建南德克公司 | 低親和力血腦障壁受體抗體及其用途 |
US10022326B2 (en) | 2012-07-18 | 2018-07-17 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
US11339209B2 (en) | 2016-11-14 | 2022-05-24 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
SG11201908052PA (en) | 2017-03-13 | 2019-09-27 | Sdg Inc | Lipid-based nanoparticles with enhanced stability |
US11077173B2 (en) | 2017-03-13 | 2021-08-03 | Sdg, Inc. | Lipid-based nanoparticles and methods using same |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
DE3916595A1 (de) * | 1989-05-22 | 1990-11-29 | Boehringer Mannheim Gmbh | Verfahren zur nichtradioaktiven messung der nucleinsaeuresynthese in eukaryontischen zellen |
US5279833A (en) * | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
CA2134773A1 (en) * | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
CA2141216A1 (en) * | 1992-07-27 | 1994-02-03 | Michael J. Micklus | Targeting of liposomes to the blood-brain barrier |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5329029A (en) * | 1992-11-05 | 1994-07-12 | Wan Barbara Y | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates |
US5631237A (en) * | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
US5681571A (en) * | 1993-10-08 | 1997-10-28 | Duotol Ab | Immunological tolerance-inducing agent |
JPH09505593A (ja) * | 1993-11-24 | 1997-06-03 | メガバイオス・コーポレイション | ピペラジンの両親媒性誘導体 |
US5674908A (en) * | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US5635380A (en) * | 1994-01-18 | 1997-06-03 | Vanderbilt University | Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5786214A (en) * | 1994-12-15 | 1998-07-28 | Spinal Cord Society | pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system |
US5780052A (en) * | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
WO1996040961A1 (en) * | 1995-06-07 | 1996-12-19 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
-
1997
- 1997-01-29 WO PCT/US1997/001284 patent/WO1997028817A1/en active IP Right Grant
- 1997-01-29 DE DE69736385T patent/DE69736385T2/de not_active Expired - Lifetime
- 1997-01-29 US US08/790,290 patent/US6077834A/en not_active Expired - Lifetime
- 1997-01-29 EP EP97906433A patent/EP0904100B1/de not_active Expired - Lifetime
- 1997-01-29 JP JP52854297A patent/JP4512882B2/ja not_active Expired - Fee Related
- 1997-01-29 AT AT97906433T patent/ATE333892T1/de not_active IP Right Cessation
- 1997-01-29 AU AU21126/97A patent/AU2112697A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2112697A (en) | 1997-08-28 |
DE69736385T2 (de) | 2007-08-23 |
WO1997028817A1 (en) | 1997-08-14 |
EP0904100A4 (de) | 2002-01-09 |
US6077834A (en) | 2000-06-20 |
EP0904100A1 (de) | 1999-03-31 |
DE69736385D1 (de) | 2006-09-07 |
EP0904100B1 (de) | 2006-07-26 |
JP4512882B2 (ja) | 2010-07-28 |
JP2000506519A (ja) | 2000-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE333892T1 (de) | Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen | |
ATE91903T1 (de) | Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel. | |
DE69505677D1 (de) | Liposomales verabreichungssystem für biologisch aktive stoffe | |
ES2082423T3 (es) | Dispositivo para la distribucion transcutanea de farmacos. | |
DE69508598T2 (de) | Mit polyethylenglycol modifizierte ceramidlipide und liposomen | |
ATE83653T1 (de) | Hautwirksame pharmaka mit liposomen als wirkstofftraeger. | |
DK0993831T3 (da) | Forbindelser og præparater til tilförsel af aktive stoffer | |
ID28003A (id) | Turunan-turunan adamantana | |
EA199900553A1 (ru) | Чрескожная терапевтическая система | |
FR2760193B1 (fr) | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules | |
DE69131347T2 (de) | Kationische lipide für die intrazelluläre abgabe von biologisch aktiven molekülen | |
DK0680750T3 (da) | Kosmetisk eller farmaceutisk sammensætning til topisk anvendelse | |
GR3032673T3 (en) | Use of an effective quantitiy of active substances for the treatment of mixed skin. | |
DK0839026T3 (da) | Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler | |
BG103552A (en) | Therapeutical forms | |
PT768867E (pt) | Forma de dosagem para a administracao de droga em formulacao liquida | |
ATE284204T1 (de) | Lipidkomplexe von sehr unlöslichen platinkomplexen | |
ATE276742T1 (de) | Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung | |
ATE223204T1 (de) | Liposomenzusammensetzung | |
GR3019171T3 (en) | System for delivering drug with enhanced bioacceptability. | |
ITMI940610A0 (it) | Platino complessi cationici trinucleari ad attivita' antitumorale e composizioni farmaceutiche che li contengono | |
FR2735132B1 (fr) | Medicament polypeptidique modifie, composition et dispositif d'administration par electrotransport le contenant | |
PT88539A (pt) | Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen | |
TR199901237T2 (xx) | Bir tienilsiklohegzilamin t�revinin tedavide yeni uygulamas�. | |
ES8704903A1 (es) | Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |